


Drinkable, liquid *in situ*-forming and tough (LIFT) hydrogels for gastrointestinal therapeutics

Gary W. Liu, Ph.D.

Ruth L. Kirschstein NRSA Postdoctoral Fellow
Langer + Traverso Laboratories
Massachusetts Institute of Technology
garywliu@mit.edu


Solid drugs may post challenges against medication compliance

 **80% of children** prefer liquids

 **37% of adults** have difficulty swallowing

 may lead to missed doses, crushed pills, or death

Bridging the advantages of solid and liquid drugs could expand drug access



easy to swallow









controlled release
mechanical toughness





T-1000, *Terminator 2: Judgment Day*


LIFT hydrogels could bridge the advantages of liquid and solid drugs



LIFT hydrogels can quickly form at timescales relevant to gastric transport





LIFT hydrogels form in *in vivo* porcine stomachs




endoscopic administration in pig



5 cm



LIFT hydrogels are safely cleared



time	ALP (U/L)	AST (U/L)	ALT (U/L)	BUN (mg/dL)	creatinine (mg/dL)
baseline	131.0 ± 25.7	18.7 ± 4.0	41.7 ± 6.8	8.7 ± 0.6	1.1 ± 0.1
24 h	132.3 ± 22.5	22.3 ± 17.2	41.7 ± 6.1	12.7 ± 4.5	1.2 ± 0.2
48 h	115.0 ± 16.5	22.3 ± 5.5	38.7 ± 5.9	9.0 ± 1.7	1.1 ± 0.2

LIFT hydrogels as a platform for a variety of drug classes



small molecules






enzymes






therapeutic bacteria



LIFT hydrogels can modulate drug pharmacokinetics



LIFT hydrogels can mitigate enzyme activity loss *in vivo*



LIFT hydrogels can mitigate viability loss of therapeutic bacteria *in vivo*



Summary and conclusions

- LIFT hydrogels are mechanically tough and can crosslink *in vivo* in porcine stomachs
- materials are tolerated in porcine models and do not exhibit toxicity
- LIFT hydrogels can modulate the release and activity of a variety of therapeutic classes through co-encapsulating excipients
- “liquid pills” could expand access to advanced therapeutics for vulnerable patient populations

Acknowledgments

Advisors

Robert Langer
Giovanni Traverso

Langer + Traverso Laboratories

Matthew J. Pickett
Jaime Cheah
Niora Fabian
Vivian R. Feig
Nina Fitzgerald
Alison Hayward
Keiko Ishida
Joshua Jenkins
Miguel Jimenez

Johannes L. P. Kuosmanen

Aaron Lopes

Wiam A. M. Madani

Seokkee Min